Emergent BioSolutions (EBS) Stock Price, News & Analysis

Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Key Stats

• Today's Range: $8.84 to $9.78
• 50-Day Range: $5.94 to $11.96
• 52-Week Range: $1.42 to $15.10
• Volume: 1.10 million shs
• Average Volume: 3.34 million shs
• Market Capitalization: $510.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Emergent BioSolutions Stock Analysis - MarketRank™

Emergent BioSolutions scored higher than 87% of companies evaluated by MarketBeat, and ranked 116th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Emergent BioSolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Emergent BioSolutions has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Emergent BioSolutions are expected to grow in the coming year, from ($1.30) to $2.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Emergent BioSolutions is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emergent BioSolutions is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Emergent BioSolutions has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.35% of the float of Emergent BioSolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent BioSolutions has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Emergent BioSolutions has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emergent BioSolutions does not currently pay a dividend.

Dividend Growth

Emergent BioSolutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.40

Percentage of Shares Shorted

13.35% of the float of Emergent BioSolutions has been sold short.

Short Interest Ratio / Days to Cover

Emergent BioSolutions has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Emergent BioSolutions has recently decreased by 10.78%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.12

News Sentiment

Emergent BioSolutions has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Emergent BioSolutions this week, compared to 4 articles on an average week.

Search Interest

Only 12 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

MarketBeat Follows

1 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Emergent BioSolutions is held by insiders.

Percentage Held by Institutions

78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EBS Stock Analysis - Frequently Asked Questions

How have EBS shares performed this year?

Emergent BioSolutions' stock was trading at $2.40 at the beginning of the year. Since then, EBS shares have increased by 292.5% and is now trading at $9.42.
View the best growth stocks for 2024 here.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) issued its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by $1.35. The biopharmaceutical company earned $254.70 million during the quarter, compared to analysts' expectations of $199.47 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 9.91% and a negative net margin of 18.55%.

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' top institutional investors include Charles Schwab Investment Management Inc. (4.11%), State Street Corp (3.53%), Oak Hill Advisors LP (2.05%) and Connor Clark & Lunn Investment Management Ltd. (1.57%). Insiders that own company stock include Kathryn C Zoon and Ronald Richard.
View institutional ownership trends.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent BioSolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/05/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:EBS
• CUSIP: 29089Q10
• CIK: 1367644
• Web: www.emergentbiosolutions.com
• Phone: (240) 631-3200
• Fax: 301-795-1899
• Employees: 1,600
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +48.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-760,500,000.00
• Net Margins: -18.55%
• Pretax Margin: -15.09%
• Return on Equity: -9.91%
• Return on Assets: -3.31%

Debt

• Debt-to-Equity Ratio: 1.30
• Current Ratio: 2.88
• Quick Ratio: 1.47

Sales & Book Value

• Annual Sales: $1.05 billion
• Price / Sales: 0.49
• Cash Flow: $1.00 per share
• Price / Cash Flow: 9.41
• Book Value: $9.38 per share
• Price / Book: 1.00

Miscellaneous

• Outstanding Shares: 54,180,000
• Free Float: 53,534,000
• Market Cap: $510.38 million
• Optionable: Optionable
• Beta: 1.57